Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Ospedale Infantile Regina Margherita, Turin

Eisai Trial Site 3, Berlin

Hopitaux de La Timone, Marseille

Istituto G Gaslini Ospedale Pediatrico IRCCS, Genoa

Istituto Nazionale Dei Tumori, Milan

Hospital Infantil Universitario Niño Jesus, Madrid

Hospital Universitario La Paz, Madrid

Azienda Ospedaliera Di Padova, Padua

Eisai Trial Site 5, Göttingen

Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna

Hospital Universitario Virgen del Rocio, Seville

Eisai Trial Site 6, Essen

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

Azienda Ospedaliera A Meyer, Florence

Eisai Trial Site 1, Aachen

Centre Oscar Lambret, Lille

Eisai Trial Site 2, Frankfurt am Main

Centre Léon Berard, Lyon

Eisai Trial Site 4, Freiburg im Breisgau

Aghia Sophia' Children's General Hospital of Athens, Athens

AHEPA University General Hospital of Thessaloniki, Thessaloniki

Ospedale Pediatrico Bambino Gesù, Rome

Fondazione Policlinico Universitario A Gemelli, Rome

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw

Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

Hospital Sant Joan de Deu, Esplugues de Llobregat

Kinderspital Zürich - Eleonorenstiftung, Zurich

Addenbrooke's Hospital, Cambridge

Southampton General Hospital, Southampton

Alder Hey Childrens Hospital, Liverpool

John Radcliffe Hospital, Oxford

Royal Marsden Hospital - Surrey, Sutton

Birmingham Children's Hospital, Birmingham

The Leeds Teaching Hospitals Charitable Foundation - Leeds Childrens Hospital (LCH), Leeds

University College London, London

Royal Manchester Childrens Hospital, Manchester

The Christie NHS Foundation Trust, Manchester

Royal Victoria Infirmary, Newcastle